Biomarkers for use in integrin therapy applications

Patent metadata

Field	Value
Publication number	US-2020248257-A1
Application number	US-201916683644-A
Country	US
Kind code	A1
Filing date	Nov 14, 2019
Priority date	Mar 29, 2012
Publication date	Aug 6, 2020
Grant date	—

Abstract

The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with αvβ6 integrin inhibition or therapy with TGF-β pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against αvβ6-integrin and/or TGF-β pathway inhibitors.

First claim

1 . A method for predicting whether a human subject who has an αvβ6-mediated disorder will respond to treatment with an αvβ6-integrin inhibitor, the method comprising:
a) providing a biological sample obtained from the human subject after administration of the αvβ6-integrin inhibitor; and
b) measuring the expression level of a gene or protein from Table 1 or a gene or protein from Table 2 in the biological sample, wherein:
(i) an increase in the expression level of the gene or protein from Table 1 relative to a control expression level; or
ii) a decrease in the expression level of the gene or protein from Table 2 relative to a control expression level,
predicts that the human subject will respond, or has an increased likelihood of responding, to treatment with the αvβ6-integrin inhibitor.

2 . The method of claim 1 , further comprising determining the phosphorylation status of SMAD2 protein in the biological sample, wherein a decrease in the phosphorylation status of SMAD2 protein after administration of the αvβ6 integrin inhibitor is a further predictor that the human subject will respond, or has an increased likelihood of responding, to treatment with the αvβ6-integrin inhibitor.

3 . The method of claim 1 , wherein the method comprises measuring any combination of at least 6 genes or proteins from Table 1, Table 2, or Tables 1 and 2.

4 . The method of claim 1 , wherein a decrease in the expression level of at least one of arachidonate 5-lipoxygenase 5 (ALOX5), fibronectin (FN1), oxidized low density lipoprotein receptor 1 (OLR1), plasminogen activator inhibitor-1 (PAI-1 or SERPINE1), transglutaminase 2 (TGM2), or triggering receptor expressed on myeloid cells 1 (TREM1) in the biological sample is measured and predicts that the human subject will respond, or has an increased likelihood of responding, to treatment with the αvβ6-integrin inhibitor.

5 . A method for predicting responsiveness of a human subject to treatment with an inhibitor of a TGF-β-signaling pathway, the method comprising:
(a) measuring the expression level of a gene or protein from Table 1 or a gene or protein from Table 2 in a first biological sample obtained from the human subject before step (b);
(b) administering the inhibitor of a TGF-β-signaling pathway to the human subject; and
(c) measuring the expression level of the gene or protein from Table 1 or the gene or protein from Table 2 in a second biological sample obtained from the human subject after step (b),
wherein an increase in the level of expression of the gene or protein from Table 1 or a decrease in the level of expression of the gene or protein from Table 2 measured in step (c), compared to the level of expression of the gene or protein measured in step (a) predicts that the human subject will respond, or has an increased likelihood of responding, to treatment with the inhibitor of the TGF-β-signaling pathway.

6 . A method of treating an αvβ6-mediated disorder in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an αvβ6 integrin inhibitor, wherein the human subject has been identified as having at least one of:
(i) a decreased expression level of a gene or protein from Table 1 in a biological sample obtained from the human subject, compared to a control expression level; or
(ii) an increased expression level of a gene or protein from Table 2 in a biological sample obtained from the human subject, compared to a control expression level.

7 . A method for predicting whether a human subject who has an αvβ6-mediated disorder will have a clinical response to treatment with an αvβ6-integrin inhibitor, the method comprising:
(a) providing a biological sample obtained from the human subject before treatment with an αvβ6-integrin inhibitor; and
(b) measuring the expression level of a gene or protein from Table 1 or a gene or protein from Table 2,
wherein a subject having
(i) a decreased expression of the gene or the protein from Table 1 relative to a control expression level, or
(ii) an increased expression of the gene or the protein from Table 2 relative to a control expression level,
is predicted to have a clinical response, or have an increased likelihood of a clinical response, to treatment with the αvβ6-integrin inhibitor.

8 . A method of treating an αvβ6-mediated disorder in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an αvβ6 integrin inhibitor, wherein the human subject has previously been administered the αvβ6 integrin inhibitor and has been identified as having at least one of:
(i) an increased expression level of a gene or protein from Table 1 in a biological sample obtained from the human subject after the previous administration of the αvβ6 integrin inhibitor, compared to a control expression level; or
(ii) a decreased expression level of a gene or protein from Table 2 in a biological sample obtained from the human subject after the previous administration of the αvβ6 integrin inhibitor, compared to a control expression level.

9 . The method of claim 1 , wherein
the biological sample is a bronchoalveolar lavage sample.

10 . The method of claim 1 , wherein
the biological sample is a tissue sample.

11 - 12 . (canceled)

13 . The method of claim 1 , wherein the αvβ6-mediated disorder is fibrosis, psoriasis, sclerosis, cancer, acute lung injury, acute kidney injury, liver injury, scleroderma, transplant, or Alports Syndrome.

14 . The method of claim 1 , wherein the αvβ6-mediated disorder is lung fibrosis or kidney fibrosis.

15 . The method of claim 1 , wherein the αvβ6-mediated disorder is idiopathic pulmonary fibrosis, radiation induced fibrosis, bleomycin induced fibrosis, or asbestos induced fibrosis.

16 . The method of claim 1 , wherein the αvβ6-mediated disorder is a cancer selected from the group consisting of a pancreatic cancer, a lung cancer, a breast cancer, a prostate cancer, a colorectal cancer, a head and neck cancer, an esophageal cancer, a skin cancer, and an endometrial cancer.

17 . The method of claim 1 , wherein the αvβ6-integrin inhibitor is an anti-αvβ6-integrin antibody.

18 . The method of claim 17 , wherein the anti-αvβ6-integrin antibody has the same CDRs as an antibody produced by a hybridoma selected from the group consisting of: 6.1A8 (ATCC accession number PTA-3647); hybridoma 6.3G9 (ATCC accession number PTA-3649); 6.8G6 (ATCC accession number PTA-3645); 6.2E5 (ATCC accession number PTA-3897); 6.2B1 (ATCC accession number PTA-3646); 7.1G10 (ATCC accession number PTA-3898); 7.7G5 (ATCC accession number PTA-3899); and 7.1C5 (ATCC accession number PTA-3900).

19 . The method of claim 17 , wherein the anti-αvβ6-integrin antibody has the same CDRs as the antibody produced by the hybridoma deposited as 6.3G9 (ATCC accession number PTA-3649), except that the light chain CDR 1 contains an asparagine to serine substitution such that the light chain CDR 1 sequence is the sequence of SASSSVSSSYLY (SEQ ID NO:1196).

20 . The method of claim 17 , wherein the anti-αvβ6-integrin antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1210.

21 . The method of claim 20 , wherein the anti-αvβ6-integrin antibody further comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1211.

22 - 23 . (canceled)

24 . A biomarker panel comprising a probe f

Assignees

• Biogen Ma Inc
• Univ California

Inventors

• Violette Shelia M
• Sheppard Dean

Classifications

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• G01N2333/70546

  Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM · CPC title

• G01N2333/495

  Transforming growth factor [TGF] · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title